beta
Trial Radar AI
Clinical Trial NCT06404268 for Stroke is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One trial matched filter criteria
Card View

Facilitating Neuroplastic Changes of Acute Stroke Survivors

Recruiting
Clinical Trial NCT06404268 is designed to study Treatment for Stroke. It is a Phase 1 Phase 2 interventional trial that is recruiting, having started on June 1, 2025, with plans to enroll 68 participants. Led by University of Maryland, Baltimore, it is expected to complete by August 31, 2028. The latest data from ClinicalTrials.gov was last updated on July 9, 2025.
Brief Summary
This project will develop a wearable rehabilitation robot suitable for in-bed acute stage rehabilitation. It involves robot-guided motor relearning, passive and active motor-sensory rehabilitation early in the acute stage post-stroke including patients who are paralyzed with no motor output. The early acute stroke rehabilitation device will be evaluated in this clinical trial.
Detailed Description
Stroke survivors often experience loss of motor control and impaired function. Immediately after stroke, there is a time-limited window of heightened plasticity during which the greatest gains in recovery occur. Therefore, early intensive sensorimotor rehabilitation post-stroke is critical in improving functional outcomes and minimizing disability. However, acute stroke survivors often receive little active training to improve mobility during their hospital stay and they are left alone during most of the day. Especially for those acute patients with no voluntary motor output, active motor training might be even less, partly due to a lack of rehabilitation protocols to detect potential motor recovering signals sensitively and facilitate neuroplastic changes. To address this unmet clinical need, this project will develop a novel wearable rehabilitation robot suitable for in-bed acute stage rehabilitation with guided motor relearning, passive and active motor-sensory rehabilitation early in the acute stage post-stroke including patients who are paralyzed with no motor output. The early acute stroke rehabilitation device will be evaluated in this clinical trial.
Official Title

Facilitating Neuroplastic Changes of Acute Stroke Survivors With Severe Hemiplegia

Conditions
Stroke
Publications
Scientific articles and research papers published about this clinical trial:
Show More
Other Study IDs
  • HP-00110205
NCT ID Number
Start Date (Actual)
2025-06-01
Last Update Posted
2025-07-09
Completion Date (Estimated)
2028-08-31
Enrollment (Estimated)
68
Study Type
Interventional
PHASE
Phase 1
Phase 2
Status
Recruiting
Keywords
Stroke
Paraplegia
Acute
Primary Purpose
Treatment
Design Allocation
Randomized
Interventional Model
Parallel
Masking
Single
Arms / Interventions
Participant Group/ArmIntervention/Treatment
ExperimentalStudy group - Wearable ankle robot rehab
Wearable rehab robot with motor relearning with real-time feedback, passive stretching under intelligent control; Active movement training with robotic assistance
Motor Relearning Training
Ankle motor control relearning training under real-time feedback
Passive Stretching
Passive stretching under intelligent robotic control
Gamed-based Active Movement Training
Active movement training through movement games with robotic assistance
Active ComparatorControl group - Limited wearable ankle robot rehab
The same wearable robot used by the study group will be used for the control group but in a limited way: no motor relearning training under real-time feedback; passive movement in the joint middle range of motion instead of passive stretching; active movement training with no robotic assistance
Passive Movement
Passive movement in the joint middle range of motion
Active Movement Training
Active movement training without robotic assistance
Ankle Torque and Motion Measurement
Ankle torque and motion measurement with no real-time feedback
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Fugl-Meyer Lower Extremity (FMLE)
The Fugl-Meyer Lower Extremity (FMLE) assessment is a measure of lower extremity (LE) motor and sensory impairments. The FMLE scale ranges from 0 to 34, with higher scores indicating better motor function.
At the beginning and end of 3-week training, and 1 month after the treatment ends]
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Active range of motion (AROM)
AROM will be measured in degrees in the ankle joint while subjects use the muscles to move the ankle.
At the beginning and end of 3-week training, and 1 month after the treatment ends
Passive Range of Motion (PROM) will be measured in degrees in the ankle joint while the robot moves the ankle of the subject strongly.
Passive Range of Motion PROM will be measured in degrees in the ankle joint while the robot moves the ankle of the subject strongly.
At the beginning and end of 3-week training, and 1 month after the treatment ends
Strength of the ankle flexor-extensor muscle will be measured in Newtons
Strength of the ankle flexor-extensor muscle will be measured in Newtons
At the beginning and end of 3-week training, and 1 month after the treatment ends
Modified Ashworth Scale (MAS)
The Modified Ashworth Scale is the most widely used assessment tool to measure resistance to limb movement in a clinic setting. Scores range from 0-4, with 6 choices. 0 (0) - No increase in muscle tone; 1 (1) - Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension; 1+ (2) - Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM (range of movement); 2 (3) - More marked increase in muscle tone through most of the ROM, but affect part(s) easily moved; 3 (4) - Considerable increase in muscle tone passive, movement difficult; 4 (5) - Affected part(s) rigid in flexion or extension.
At the beginning and end of 3-week training, and 1 month after the treatment ends
Berg Balance Scale
The Berg balance scale is used to objectively determine a patient's ability (or inability) to safely balance during a series of predetermined tasks. The Berg balance scale ranges from 0 to 56. It is a 14-item list with each item consisting of a five-point ordinal scale ranging from 0 to 4, with 0 indicating the lowest level of function and 4 the highest level of function.
At the beginning and end of 3-week training, and 1 month after the treatment ends
10-meter Walk Test
The 10 Meter Walk Test is a performance measure used to assess walking speed in meters per second over a short distance at the beginning and end of 3-week training, and 1 month after the treatment ends. It can be employed to determine functional mobility and gait function.
At the beginning and end of 3-week training, and 1 month after the treatment ends
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
30 Years
Eligible Sexes
All
  • Acute first time unilateral hemispheric stroke (hemorrhagic or ischemic stroke, 24 hours after admission to 1 month post-stroke at the start of the proposed treatment)
  • Hemiplegia or hemiparesis
  • 0≤Manual Muscle Testing (MMT)<=2
  • Age 30-85
  • Ankle impairments including stiff calf muscles and/or inadequate dorsiflexion

  • Medically not stable
  • Associated acute medical illness that interferes with ability to training and exercise
  • No impairment or very mild ankle impairment of ankle
  • Severe cardiovascular problems that interfere with ability to perform moderate movement exercises
  • Cognitive impairment or aphasia with inability to follow instructions
  • Severe pain in legs
  • Severe ankle contracture greater than 15° plantar flexion (when pushing ankle to dorsiflexion)
  • Pressure ulcer, recent surgical incision or active skin disease with open wounds present below knee
University of Maryland, Baltimore logoUniversity of Maryland, Baltimore200 active trials to explore
The University of Texas Health Science Center, Houston logoThe University of Texas Health Science Center, Houston
Study Responsible Party
Li-Qun Zhang, Principal Investigator, Professor, University of Maryland, Baltimore
Study Central Contact
Contact: Soh-Hyun Hur, 410 706-8625, [email protected]
2 Study Locations in 1 Countries

Maryland

University of Maryland Baltimore, Baltimore, Maryland, 21201, United States
Dali Xu, PhD, Contact
Peiwen Fu, BS, Contact
Recruiting
UMROI, Baltimore, Maryland, 21207, United States
Dali Xu, Contact
Peiwen Fu, Contact
Recruiting